Eli Lilly has opened up a second market for its new Alzheimer's disease therapy Kisunla, after Japan followed the US in ...

Eli Lilly has received approval from the Ministry of Health, Labour and Welfare (MHLW) in Japan for Kisunla (donanemab-azbt) ...

Kisunla (donanemab) is the second in a new generation of amyloid-targeting medicines to reach the Japanese market after Eisai ...

Eli Lilly's Kisunla receives Japanese approval for the treatment of early symptomatic Alzheimer's disease: Indianapolis Wednesday, September 25, 2024, 09:00 Hrs [IST] The Ministry ...

Japan's health ministry has officially approved the domestic production and sale of a new drug for Alzheimer's disease.

"This has been a fruitful USA visit, covering diverse programmes and focusing on a series of subjects aimed at making our planet better. Here are the highlights," PM Modi said in a post on X. The US ...

Seemingly overnight, Arizona has emerged as a big player in the rejuvenated U.S. semiconductor industry, What does that mean, ...

Japan, with its rapidly aging population, is expected to have more than 5 million patients with dementia by 2030. Alzheimer’s ...

This briefing covers notable health news: the US is donating 1 million mpox vaccine doses to Africa, AstraZeneca’s breast ...

Eli Lilly's Kisunla (donanemab) has been approved in Japan for early symptomatic Alzheimer's, including mild cognitive ...

(RTTNews) - Eli Lilly and Company (LLY) Tuesday said its Kisunla for the treatment of adults with early symptomatic Alzheimer's disease has been approved by the Ministry of Health, Labour and Welfare ...

Eli Lilly’s (NYSE:LLY) treatment for early Alzheimer's disease has been approved for use in Japan. Kisunla (donanemab-azbt), ...